Suitability Allegations in Florida: When Product Complexity Becomes a Liability

Complex investment products are not inherently unsuitable. They may provide diversification, income, downside protection, leverage, or exposure to markets that would otherwise be difficult to access. However, when a product’s structure, risks, costs, or performance characteristics are not fully understood (or are not adequately matched to the investor), complexity can quickly become a source of regulatory and legal exposure.

For Florida broker-dealers, investment advisers, and associated persons, the central concern is rarely complexity alone. The greater issue is whether the financial professional understood the product, evaluated the customer’s circumstances, communicated the material risks, and maintained records that support the recommendation.

When one of those elements is missing, an investment loss can develop into a suitability allegation, regulatory investigation, customer arbitration, or enforcement action.

What Makes an Investment Product “Complex”?

There is no single definition that captures every complex investment product. The Financial Industry Regulatory Authority (FINRA) generally views a product as complex when its features make it difficult for a retail investor to understand its essential characteristics and risks.

Products that may receive heightened scrutiny include:

• Structured notes
• Leveraged or inverse exchange-traded products
• Options and options-based strategies
• Non-traded real estate investment trusts
• Business development companies
• Variable annuities
• Alternative investments
• Private placements
• Volatility-linked products
• Products tied to commodities, derivatives, or market indexes

A product does not become improper merely because it contains complicated features. Some sophisticated investors may understand and appropriately use these investments. The risk arises when the product is recommended without sufficient due diligence, sold to an investor whose profile does not support it, or presented in a way that minimizes its limitations.

As FINRA has emphasized in its guidance concerning complex products and options, product complexity may require additional scrutiny, supervision, investor education, and documentation.

Suitability, Regulation Best Interest, and Fiduciary Duties

The legal standard applied to a recommendation depends on the financial professional’s role, the customer involved, and the nature of the relationship.

FINRA Rule 2111 historically established three primary suitability obligations:

1. Reasonable-basis suitability: The firm or associated person must understand the product and have a reasonable basis to believe it could be suitable for at least some investors.
2. Customer-specific suitability: The recommendation must be appropriate for the particular customer based on the customer’s investment profile.
3. Quantitative suitability: A series of transactions must not become excessive or unsuitable when viewed together.

For recommendations to retail customers that are subject to the Securities and Exchange Commission’s Regulation Best Interest, Regulation Best Interest generally governs instead of FINRA Rule 2111. It requires broker-dealers and their associated persons to act in the retail customer’s best interest at the time a recommendation is made and not place their own financial interests ahead of the customer’s interests.

Investment advisers operate under a fiduciary standard. Their obligations may include evaluating whether an investment is consistent with the client’s objectives, providing full and fair disclosure of material facts and conflicts, seeking best execution, and monitoring the account when the advisory relationship requires it.

Florida-registered firms and associated persons may also face examination or enforcement by the Florida Office of Financial Regulation (OFR) under the Florida Securities and Investor Protection Act and applicable administrative rules.

Although the terminology and legal standards differ, regulators often focus on the same underlying questions: Was the product understood? Was the recommendation justified? Were conflicts disclosed? Was the investor given accurate information? Can the firm prove it?

How Product Complexity Creates Liability

Complex-product allegations often begin after a decline in value, an unexpected tax consequence, a liquidity problem, or the failure of a product to perform as the investor anticipated.

A customer may claim that the investment was described as safe, conservative, guaranteed, or income-producing without an adequate explanation of the conditions attached to those descriptions. An investor may also allege that the financial professional did not explain surrender charges, caps on returns, call provisions, leverage, illiquidity, credit risk, or the possibility of losing principal.

Common allegations include:

• The product was inconsistent with the customer’s age, income, net worth, tax status, or liquidity needs.
• The recommendation conflicted with the customer’s stated risk tolerance.
• The investment created excessive concentration in one product, asset class, issuer, or strategy.
• The representative relied on marketing materials without independently understanding the product.
• Material fees, commissions, incentives, or conflicts were not adequately disclosed.
• The customer signed disclosure documents but did not genuinely understand the product’s operation.
• The firm failed to supervise the recommendation or identify a pattern of higher-risk sales.

These cases are highly fact-specific. A loss alone does not establish that a recommendation was improper. Markets fluctuate, and even an appropriately recommended product can decline in value. The defense often depends on what the financial professional knew, what was communicated, and what the contemporaneous records demonstrate.

Disclosure Forms Are Important…but Not Always Sufficient

Signed disclosures can be valuable evidence. They may show that the investor received information about fees, liquidity restrictions, market risk, or the possibility of loss.

However, a signed form does not automatically resolve every allegation.

Regulators and arbitrators may examine whether the disclosure was clear, whether it was consistent with the verbal sales presentation, and whether the investor had a meaningful opportunity to understand the information. They may also question whether a dense offering document was used as a substitute for an actual discussion.

The more complicated the product, the more important it becomes to document the explanation provided. A record stating that “risks were discussed” may offer less protection than notes identifying the specific risks, customer questions, alternative products considered, and reasons the recommendation was selected.

The Role of Supervisory Systems

Complex-product liability is not limited to the individual who made the recommendation. A firm may face allegations that its supervisory system was not reasonably designed to identify and address foreseeable risks.

Effective supervision may include:

• A formal product-review and approval process
• Training on product structure, costs, risks, and appropriate customer profiles
• Procedures for identifying concentration and liquidity concerns
• Enhanced review of recommendations involving older or vulnerable investors
• Controls addressing conflicts and sales incentives
• Review of communications and marketing materials
• Exception reports and escalation procedures
• Periodic testing of written supervisory procedures

FINRA has advised firms to consider heightened supervisory and compliance procedures for products whose features may be difficult for investors to understand. A firm that permits the sale of a complicated investment without ensuring its representatives understand it may struggle to defend the recommendation later.

Responding to an OFR, FINRA, or SEC Inquiry

A suitability or complex-product inquiry should be taken seriously from the outset. Early responses can influence the direction of an investigation and may become part of the permanent regulatory record.

The firm or financial professional should preserve relevant materials, including:

• New account documents
• Customer profile updates
• Risk-tolerance questionnaires
• Investment policy statements
• Emails and text messages
• Product training records
• Due-diligence materials
• Supervisory approvals
• Account statements
• Notes of customer meetings and telephone calls
• Records concerning fees, commissions, and conflicts

It is also important to reconstruct the circumstances as they existed when the recommendation was made. Evaluating the recommendation solely through the lens of a later loss can distort the analysis. The relevant question is generally whether the recommendation was supportable based on the information reasonably available at that time.

Firms should avoid submitting rushed explanations, incomplete document productions, or speculative answers. Regulatory inquiries often require a coordinated response that addresses the specific allegation while remaining consistent with the firm’s records and supervisory procedures.

Reducing Exposure Before a Complaint Occurs

The strongest defense begins before an investor complains.

Firms should review whether their procedures keep pace with the products they approve. Representatives should understand not only the potential benefits of an investment but also how it may behave under unfavorable market conditions.

Customer profiles should be updated when financial circumstances or objectives change. Concentration should be evaluated across the entire portfolio rather than one transaction at a time. Discussions about risks, alternatives, liquidity, costs, and conflicts should be documented in practical detail.

Most importantly, firms should remember that complexity increases the burden of explanation. If a recommendation cannot be clearly explained, carefully matched to the investor, and supported in the records, the product’s sophistication may become a liability rather than an advantage.

Protecting Your Registration and Your Firm

Suitability and complex-product allegations can expose financial professionals and firms to customer claims, administrative sanctions, fines, supervisory restrictions, and reputational harm. They may also lead regulators to examine broader sales practices extending beyond the original transaction.

Howell, Buchan & Strong represents broker-dealers, investment advisers, associated persons, and other financial professionals in matters involving the Florida Office of Financial Regulation, FINRA, the SEC, and other regulatory authorities. If you are facing an examination, investigation, customer complaint, or enforcement action involving complex investment products, experienced legal counsel can help you evaluate the allegations, preserve the record, and develop an informed response.